Antisense Oligonucleotides: Insights from Preclinical Studies and Clinical Trials

RNA Technologies

Volumn , Issue , 2010, Pages 285-303

  Kunze, Doreen ^a   Kraemer, Kai ^a   Fuessel, Susanne ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Antisense oligonucleotides; Asthma; Cancer treatment; Cardiovascular disease; Clinical trials; Duchenne muscular dystrophy; In vivo studies; Virus infection

Indexed keywords

EID: 82755167541     PISSN: 21979731     EISSN: 21979758     Source Type: Book Series    
DOI: 10.1007/978-3-642-12168-5_13     Document Type: Chapter

References (72)

1. Aartsma-Rus A, Fokkema I, Verschuuren J et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30:293–299
2. Advani R, Lum BL, Fisher GA et al (2005) A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Invest New Drugs 23:467–477
3. Agrawal S, Kandimalla ER (2001) Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets 1:197–209
4. Agrawal S, Kandimalla ER (2003) Modulation of toll-like receptor 9 responses through synthetic immunostimulatory motifs of DNA. Ann NY Acad Sci 1002:30–42
5. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581–8589
6. Anderson EM, Miller P, Ilsley D et al (2006) Gene profiling study of G3139-and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Cancer Gene Ther 13:406-414
7. Bates PJ, Laber DA, Miller DM et al (2009) Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 86:151–164
8. Bedikian AY, Millward M, Pehamberger H et al (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738–4745
9. Bogdahn U, Schneider T, Oliushine V et al (2009) Randomized, active-controlled phase IIb study with trabedersen (AP 12009) in recurrent or refractory high-grade glioma patients: Basis for phase III endpoints. J Clin Oncol 27:2037
10. Call JA, Eckhardt SG, Camidge DR (2008) Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 9:1002–1011
11. Cao C, Shinohara ET, Li H et al (2005) Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 63:1228–1236
12. Chanan-Khan AA, Niesvizky R, Hohl RJ et al (2009) Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 50:559–565
13. 0-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97:1287–1296
14. Chi KN, Zoubeidi A, Gleave ME (2008) Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs 17:1955–1962
15. Chi KN, Hotte SJ, Yu E et al (2009) Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 27:5012
16. Cooper CL, Davis HL, Angel JB et al (2005) CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19:1473–1479
17. Crooke ST (2004a) Antisense strategies. Curr Mol Med 4:465–487
18. Crooke ST (2004b) Progress in antisense technology. Annu Rev Med 55:61–95
19. Dapić V, Abdomerović V, Marrington R et al (2003) Biophysical and biological properties of quadruplex oligodeoxyribonucleotides. Nucleic Acids Res 31:2097–2107
20. Dean E, Jodrell D, Connolly K et al (2009) Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. Clin Oncol 27:1660–1666
21. Elmén J, Lindow M, Silahtaroglu A et al (2007) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36:1153–1162
22. Elmén J, Lindow M, Sch€utz S et al (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452:896–899
23. Fisker N, Westergaard M, Hansen HF et al (2007) Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids 26:1427–1430
24. Gauvreau GM, Boulet LP, Cockcroft DW et al (2008) Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 177:952–958
25. Gekeler V, Gimmnich P, Hofmann HP et al (2006) G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16:83–93
26. Goel S, Desai K, Bulgaru A et al (2003) A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clin Cancer Res 9:4069–4076
27. Guimond A, Viau E, Aubé P et al (2008) Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates. Pulm Pharmacol Ther 21:845–854
28. Hansen JB, Fisker N, Westergaard M et al (2008) SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 7:2736–2745
29. Hartmann G, Weeratna RD, Ballas ZK et al (2000) Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164:1617–1624
30. Henry SP, Giclas PC, Leeds J et al (1997) Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther 281:810–816
31. Jason TLH, Koropatnicka J, Berg RW (2004) Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 201:66–83
32. Jearawiriyapaisarn N, Moulton HM, Buckley B et al (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16:1624–1629
33. Kastelein JJ, Wedel MK, Baker BF et al (2006) Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114:1729–1735
34. Klasa RJ, Gillum AM, Klem RE et al (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12:193–213
35. Kraemer K, Schmidt U, Fuessel S et al (2006) Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. Int J Cancer 119:1276–1284
36. Kunze D, Wuttig D, Kausch I et al (2008) Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 32:1049–1056
37. Kurreck J (2003) Antisense technologies Improvement through novel chemical modifications. Eur J Biochem 270:1628–1644
38. Lacasse EC, Kandimalla ER, Winocour P et al (2005) Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640. Ann NY Acad Sci 1058:215–234
39. Lai JC, Benimetskaya L, Santella RM et al (2003) G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther 2:1031–1043
40. Leonetti C, Biroccio A, D’Angelo C et al (2007) Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 67:1475–1485
41. Lin C, Papadopoulos K, Patnaik A et al (2007) Oblimersen can be administered by subcutaneous (SC) and brief intravenous (IV) infusion: Clinical pharmacokinetics and pharmacodynamics (PK/PD) in patients with advanced cancer. J Clin Oncol 25:14083
42. Marchand C, Pourquier P, Laco GS et al (2002) Interaction of human nuclear topoisomerase I with guanosine quartet-forming and guanosine-rich single-stranded DNA and RNA oligonucleotides. J Biol Chem 277:8906–8911
43. Marcucci G, Moser B, Blum W et al (2007) A phase III randomized trial of intensive induction and consolidation chemotherapy þ/ oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. J Clin Oncol 25:7012
44. Miyake H, Chi KN, Gleave ME (2000) Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 6:1655–1663
45. 0-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 268: 14514–14522
46. Niepmann M (2009) Activation of hepatitis C virus translation by a liver-specific microRNA. Cell Cycle 8:1473–1477
47. O’Brien S, Moore JO, Boyd TE et al (2007) Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 25:1114–1120
48. Oettle H, Hilbig A, Seufferlein T et al (2009) Interim results of the phase I/II study of trabedersen (AP 12009) in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma. J Clin Oncol 27:4619
49. Reed JC (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541–546
50. Rubenstein M, Tsui P, Guinan P (2009) Treatment of prostate and breast tumors employing mono-and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2. Med Oncol. doi:10.1007/s12032-009-9254-4
51. Ryan BM, O’Donovan N, Duffy MJ (2009) Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. doi:10.1016/j.ctrv.2009.05.003
52. Schimmer AD, Dalili S, Batey RA et al (2006) Targeting XIAP for the treatment of malignancy. Cell Death Differ 13:179–188
53. Schlingensiepen KH, Fischer-Blass B, Schmaus S et al (2008) Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 177:137–50
54. Sp€ankuch B, Steinhauser I, Wartlick H et al (2008) Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 10:223–234
55. Stahel RA, Zangemeister-Wittke U (2003) Antisense oligonucleotides for cancer therapy-an overview. Lung Cancer 41(Suppl 1):S81–88
56. Stessl M, Marchetti-Deschmann M, Winkler J et al (2009) A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. J Proteomics. doi:10.1016/j.jprot. 2009.06.001
57. Talbot D, Davies J, Callies S et al (2008) First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. J Clin Oncol 26:3518
58. Talbot D, Davies J, Olsen A et al (2009) Pharmacodynamic (PD) evaluation of LY2181308 in patients with metastatic malignancies. J Clin Oncol 27:3507
59. Tillman LG, Geary RS, Hardee GE (2007) Oral delivery of antisense oligonucleotides in man. J Pharm Sci 97:225–236
60. Tilly H, Coiffier B, Michallet AS et al (2007) Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukaemia (CLL). J Clin Oncol 25:7036
61. van Deutekom JC, Janson AA, Ginjaar IB et al (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677–2686
62. Vollmer J, Krieg AM (2009) Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61:195–204
63. Wang Y, Liu X, Chen L et al (2009) Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur J Nucl Med Mol Imaging. doi:10.1007/s00259-009-1201-2
64. Warfield KL, Swenson DL, Olinger GG et al (2006) Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog 2:e1
65. Wasan EK, Waterhouse D, Sivak O et al (2002) Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. Int J Pharm 241:57–64
66. Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer 43:1529–1544
67. Yokota T, Lu QL, Partridge T et al (2009) Efficacy of systemic morpholino exon-skipping in duchenne dystrophy dogs. Ann Neurol 65:667–676
68. Yu RZ, Kim TW, Hong A et al (2007) Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35:460–468
69. 0-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 48:39–50
70. 0-O-(2-methoxy)ethyl chemistry. J Pharmacol Exp Ther 298:934–940
71. Zellweger T, Chi K, Miyake H et al (2002) Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 8:3276–3284
72. Zhang Q, Zhou W, Kundu S et al (2006) The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro. BJU Int 98:452–460